Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cogent Biosciences, Inc.

7.67
+0.50006.97%
Pre-market: 8.090.4200+5.48%05:51 EST
Volume:1.29M
Turnover:9.76M
Market Cap:873.23M
PE:-3.95
High:7.76
Open:7.23
Low:7.18
Close:7.17
Loading ...

Company Profile

Company Name:
Cogent Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
205
Office Location:
275 Wyman Street,3rd Floor,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
- -
Introduction:
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Directors

Name
Position
Andrew Robbins
Chief Executive Officer, President and Director
Peter Harwin
Chairman and Director
Arlene M. Morris
Director
Chris Cain
Director
Karen Ferrante
Director
Matthew E. Ros
Director
Todd Shegog
Director

Shareholders

Name
Position
Andrew Robbins
Chief Executive Officer, President and Director
John Green
Chief Financial Officer
Jessica Sachs
Chief Medical Officer